Isolating multiple formats of human monoclonal neutralizing antibodies against SARS-CoV-2 by in vitro site-directed antibody screening

Neutralizing antibody is one of the most effective interventions for acute pathogenic infection. Currently, over three million people have been identified for SARS-CoV-2 infection but SARS-CoV-2-specific vaccines and neutralizing antibodies are still lacking. SARS-CoV-2 infects host cells by interacting with angiotensin converting enzyme-2 (ACE2) via the S1 receptor-binding domain (RBD) of its surface spike glycoprotein. Therefore, blocking the interaction of SARS-CoV-2-RBD and ACE2 by antibody would cause a directly neutralizing effect against virus. In the current study, we selected the ACE2 interface of SARS-CoV-2-RBD as the targeting epitope for neutralizing antibody screening. We performed site-directed screening by phage display and finally obtained one IgG antibody (4A3) and several domain antibodies. Among them, 4A3 and three domain antibodies (4A12, 4D5, and 4A10) were identified to act as neutralizing antibodies due to their capabilities to block the interaction between SARS-CoV-2-RBD and ACE2-positive cells. The domain antibody 4A12 was predicted to have the best accessibility to all three ACE2-interfaces on the spike homotrimer. Pseudovirus and authentic SARS-CoV-2 neutralization assays showed that all four antibodies could potently protect host cells from virus infection. Overall, we isolated multiple formats of SARS-CoV-2-neutralizing antibodies via site-directed antibody screening, which could be promising candidate drugs for the prevention and treatment of COVID-19.

[1]  Jianhua Du,et al.  Blocking antibodies against SARS-CoV-2 RBD isolated from a phage display antibody library using a competitive biopanning strategy , 2020, bioRxiv.

[2]  Q. Jin,et al.  Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain , 2020, Nature Communications.

[3]  Wenhui Li,et al.  The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement , 2020, bioRxiv.

[4]  J. Zhao,et al.  Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor , 2020, Cellular & Molecular Immunology.

[5]  Baoying Huang,et al.  Robust neutralization assay based on SARS-CoV-2 S-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressed BHK21 cells , 2020, bioRxiv.

[6]  Lu Lu,et al.  Fully human single-domain antibodies against SARS-CoV-2 , 2020, bioRxiv.

[7]  Linqi Zhang,et al.  Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.

[8]  Lei Liu,et al.  Potent human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, bioRxiv.

[9]  Shibo Jiang,et al.  Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine , 2020, Cellular & Molecular Immunology.

[10]  Nicholas C. Wu,et al.  A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV , 2020, Science.

[11]  R. Scheuermann,et al.  A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2 , 2020, Cell Host & Microbe.

[12]  Frank Grosveld,et al.  A human monoclonal antibody blocking SARS-CoV-2 infection , 2020, Nature Communications.

[13]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[14]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[15]  Qiang Zhou,et al.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 , 2020, Science.

[16]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[17]  E. Holmes,et al.  A new coronavirus associated with human respiratory disease in China , 2020, Nature.

[18]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[19]  E. Holmes,et al.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.

[20]  J. Nie,et al.  Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2 , 2020, Emerging microbes & infections.

[21]  Fang Li,et al.  Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry , 2019, Journal of Virology.

[22]  Zhènglì Shí,et al.  Origin and evolution of pathogenic coronaviruses , 2018, Nature Reviews Microbiology.

[23]  L. Goulart,et al.  Phage display: an important tool in the discovery of peptides with anti-HIV activity. , 2018, Biotechnology advances.

[24]  H. Ploegh,et al.  Exploiting Nanobodies' Singular Traits. , 2018, Annual review of immunology.

[25]  Catharine I Paules,et al.  Monoclonal Antibodies for Emerging Infectious Diseases - Borrowing from History. , 2018, The New England journal of medicine.

[26]  Shibo Jiang,et al.  Single-Domain Antibodies As Therapeutics against Human Viral Diseases , 2017, Front. Immunol..

[27]  A. Walls,et al.  Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion , 2017, Proceedings of the National Academy of Sciences.

[28]  Elissa M. Hudspeth,et al.  Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate , 2017, Journal of Pharmaceutical Sciences.

[29]  Fang Li,et al.  Structure, Function, and Evolution of Coronavirus Spike Proteins. , 2016, Annual review of virology.

[30]  Frank DiMaio,et al.  Automated structure refinement of macromolecular assemblies from cryo-EM maps using Rosetta , 2016, bioRxiv.

[31]  D. Dimitrov,et al.  Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn , 2015, mAbs.

[32]  W. Marasco,et al.  Phage and Yeast Display , 2015, Microbiology spectrum.

[33]  S. Muyldermans,et al.  Nanobody-based products as research and diagnostic tools. , 2014, Trends in biotechnology.

[34]  P. Bowers,et al.  Mammalian cell display for the discovery and optimization of antibody therapeutics. , 2014, Methods.

[35]  Serge Muyldermans,et al.  Nanobodies: natural single-domain antibodies. , 2013, Annual review of biochemistry.

[36]  Prida Malasit,et al.  Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans , 2010, Science.

[37]  A. Osterhaus,et al.  Vaccine-induced enhancement of viral infections , 2008, Vaccine.

[38]  D. Christ,et al.  Selection of human antibody fragments by phage display , 2007, Nature Protocols.

[39]  Shibo Jiang,et al.  Cross-Neutralization of Human and Palm Civet Severe Acute Respiratory Syndrome Coronaviruses by Antibodies Targeting the Receptor-Binding Domain of Spike Protein , 2006, The Journal of Immunology.

[40]  S. Harrison,et al.  Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor , 2005, Science.

[41]  Wenhui Li,et al.  A 193-Amino Acid Fragment of the SARS Coronavirus S Protein Efficiently Binds Angiotensin-converting Enzyme 2* , 2004, Journal of Biological Chemistry.

[42]  John L. Sullivan,et al.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.

[43]  Y. Kawaoka,et al.  Antibody‐dependent enhancement of viral infection: molecular mechanisms and in vivo implications , 2003, Reviews in medical virology.

[44]  Y. Kawaoka,et al.  Antibody-Dependent Enhancement of Ebola Virus Infection , 2003, Journal of Virology.